PUBLISHER: DelveInsight | PRODUCT CODE: 1397400
PUBLISHER: DelveInsight | PRODUCT CODE: 1397400
"BREYANZI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about BREYANZI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the BREYANZI for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BREYANZI for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BREYANZI market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
BREYANZI (Lisocabtagene maraleucel) is an investigational CAR-T-cell therapy designed to target CD19, a surface glycoprotein expressed during normal B-cell development. Liso-cel CAR-T-cells aim to target and kill non-Hodgkin lymphoma cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain. The defined composition of liso-cel CAR-positive viable T cells consisting of CD8 and CD4 components may reduce product variability; however, the clinical significance of the defined composition is unknown. Liso-cel was initially developed by Juno Therapeutics; later, Celgene acquired the company in 2018; in 2019, Celgene was acquired by Bristol Myers Squibb.
As per the company 2022, recent corporate presentation, BREYANZI is a best-in-class anti-CD19 with the broadest US 2L LBCL label, and the company anticipates continuing capacity expansion in 2023.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of BREYANZI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of BREYANZI for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.